KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Inventory (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Change in Inventory data on record, last reported at -$14.2 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 29.09% year-over-year to -$14.2 million; the TTM value through Dec 2025 reached $30.3 million, up 23.67%, while the annual FY2025 figure was $30.3 million, 23.67% up from the prior year.
  • Change in Inventory reached -$14.2 million in Q4 2025 per EBS's latest filing, down from $17.6 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $99.9 million in Q1 2021 and bottomed at -$55.1 million in Q4 2022.
  • Average Change in Inventory over 5 years is $8.9 million, with a median of $6.5 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: crashed 740.7% in 2022, then surged 17900.0% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $8.6 million in 2021, then plummeted by 740.7% to -$55.1 million in 2022, then surged by 53.54% to -$25.6 million in 2023, then skyrocketed by 57.03% to -$11.0 million in 2024, then dropped by 29.09% to -$14.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$14.2 million in Q4 2025, $17.6 million in Q3 2025, and $24.7 million in Q2 2025.